RBC Capital lowered the firm’s price target on Bausch Health (BHC) to $10 from $11 and keeps a Sector Perform rating on the shares ahead of its ...

Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long ...

RBC Capital analyst Douglas Miehm assigned a Hold rating to Bausch Health Companies (BHC – Research Report) today and set a price target of ...

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a ...

Shares of Bausch Health Companies Inc. (NYSE:BHC – Get Free Report) have been given a consensus rating of “Hold” by the seven ratings firms that are presently covering the stock, Marketbeat Ratings ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for ...

Merit Financial Group LLC acquired a new position in shares of Bausch Health Companies Inc. (NYSE:BHC – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 28,245 shares ...

Bausch + Lomb in December confirmed that a sale was “one of several options being explored to complete a full separation from Bausch Health Companies Inc.,” making the statement in response to ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.